NZ616166B2 - Drug delivery device - Google Patents
Drug delivery device Download PDFInfo
- Publication number
- NZ616166B2 NZ616166B2 NZ616166A NZ61616612A NZ616166B2 NZ 616166 B2 NZ616166 B2 NZ 616166B2 NZ 616166 A NZ616166 A NZ 616166A NZ 61616612 A NZ61616612 A NZ 61616612A NZ 616166 B2 NZ616166 B2 NZ 616166B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- cartridge holder
- dose setting
- setting mechanism
- drug delivery
- delivery device
- Prior art date
Links
- 229940089114 Drug Delivery Device Drugs 0.000 title claims abstract description 26
- 238000010168 coupling process Methods 0.000 claims abstract description 47
- 238000005859 coupling reaction Methods 0.000 claims abstract description 47
- 230000001808 coupling Effects 0.000 claims abstract description 39
- 230000000875 corresponding Effects 0.000 claims abstract description 18
- 239000003814 drug Substances 0.000 claims description 10
- 229940079593 drugs Drugs 0.000 claims description 7
- 230000000694 effects Effects 0.000 claims 1
- 229940090045 Cartridge Drugs 0.000 description 108
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exendin-4 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 description 50
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 49
- 101700024131 EXE4 Proteins 0.000 description 46
- 229960001519 exenatide Drugs 0.000 description 46
- 239000000306 component Substances 0.000 description 35
- 102000004877 Insulin Human genes 0.000 description 24
- 108090001061 Insulin Proteins 0.000 description 24
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 17
- 102000004965 antibodies Human genes 0.000 description 15
- 108090001123 antibodies Proteins 0.000 description 15
- 235000001014 amino acid Nutrition 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 9
- 150000003839 salts Chemical class 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 239000000427 antigen Substances 0.000 description 6
- 102000038129 antigens Human genes 0.000 description 6
- 108091007172 antigens Proteins 0.000 description 6
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 5
- 206010012601 Diabetes mellitus Diseases 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000035693 Fab Effects 0.000 description 3
- 150000004676 glycans Polymers 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 150000004804 polysaccharides Polymers 0.000 description 3
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Enoxaparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 229960002897 Heparin Drugs 0.000 description 2
- ZFGMDIBRIDKWMY-PASTXAENSA-N Heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 2
- 229940088597 Hormone Drugs 0.000 description 2
- 102000018358 Immunoglobulins Human genes 0.000 description 2
- 108060003951 Immunoglobulins Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 2
- 150000001447 alkali salts Chemical class 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 210000004027 cells Anatomy 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 101710038873 glc-1 Proteins 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 239000004026 insulin derivative Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000003055 low molecular weight heparin Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- -1 or K+ Chemical compound 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 230000000069 prophylaxis Effects 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- RWHUEXWOYVBUCI-ITQXDASVSA-N (2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-naphthalen-2-yl-1-oxopropan-2-yl]amino]-3-( Chemical compound C([C@@H](C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 RWHUEXWOYVBUCI-ITQXDASVSA-N 0.000 description 1
- CUWODFFVMXJOKD-UVLQAERKSA-N (2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-[(2S)-2-(ethylcarbamoyl)pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]amino]-3-(4-hy Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 description 1
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 1
- 206010002383 Angina pectoris Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010003246 Arthritis Diseases 0.000 description 1
- 210000003719 B-Lymphocytes Anatomy 0.000 description 1
- 108010037003 Buserelin Proteins 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 description 1
- 230000037250 Clearance Effects 0.000 description 1
- 108010000437 Deamino Arginine Vasopressin Proteins 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 229960005153 Enoxaparin sodium Drugs 0.000 description 1
- 229940088598 Enzyme Drugs 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 240000003550 Eusideroxylon zwageri Species 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- 102400000932 Gonadoliberin-1 Human genes 0.000 description 1
- 108010084340 Gonadotropin-Releasing Hormone Proteins 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- 229960002913 Goserelin Drugs 0.000 description 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- 241000282619 Hylobates lar Species 0.000 description 1
- 210000003016 Hypothalamus Anatomy 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- 229960004338 Leuprorelin Drugs 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- 208000002780 Macular Degeneration Diseases 0.000 description 1
- 208000010125 Myocardial Infarction Diseases 0.000 description 1
- 108010021717 Nafarelin Proteins 0.000 description 1
- 229960002333 Nafarelin Drugs 0.000 description 1
- 229920000272 Oligonucleotide Polymers 0.000 description 1
- 229940055729 Papain Drugs 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 210000002381 Plasma Anatomy 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 208000003385 Rhinitis, Allergic, Seasonal Diseases 0.000 description 1
- 102000005632 Single-Chain Antibodies Human genes 0.000 description 1
- 108010070144 Single-Chain Antibodies Proteins 0.000 description 1
- 108010010056 Terlipressin Proteins 0.000 description 1
- BENFXAYNYRLAIU-QSVFAHTRSA-N Terlipressin Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)CN)CSSC1 BENFXAYNYRLAIU-QSVFAHTRSA-N 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 229940035295 Ting Drugs 0.000 description 1
- 229960004824 Triptorelin Drugs 0.000 description 1
- 210000003462 Veins Anatomy 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000003042 antagnostic Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 201000001320 atherosclerosis Diseases 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 229960002719 buserelin Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000035512 clearance Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 150000001945 cysteines Chemical class 0.000 description 1
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 1
- NFLWUMRGJYTJIN-PNIOQBSNSA-N desmopressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-PNIOQBSNSA-N 0.000 description 1
- 229960004281 desmopressin Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 108010015174 exendin 3 Proteins 0.000 description 1
- LMHMJYMCGJNXRS-IOPUOMRJSA-N exendin-3 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@H](C)O)[C@H](C)O)C(C)C)C1=CC=CC=C1 LMHMJYMCGJNXRS-IOPUOMRJSA-N 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 125000000267 glycino group Chemical group [H]N([*])C([H])([H])C(=O)O[H] 0.000 description 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
- 229960001442 gonadorelin Drugs 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229910000042 hydrogen bromide Chemical class 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 239000000960 hypophysis hormone Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 125000001419 myristoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002797 proteolythic Effects 0.000 description 1
- 230000001105 regulatory Effects 0.000 description 1
- MAKUBRYLFHZREJ-JWBQXVCJSA-M sodium;(2S,3S,4R,5R,6R)-3-[(2S,3R,5S,6R)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylate Chemical compound [Na+].CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@H](O)[C@H]1O MAKUBRYLFHZREJ-JWBQXVCJSA-M 0.000 description 1
- 229960004532 somatropin Drugs 0.000 description 1
- 241001223854 teleost fish Species 0.000 description 1
- 229960003813 terlipressin Drugs 0.000 description 1
- VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 description 1
- 229960005486 vaccines Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/24—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic
- A61M2005/2485—Ampoule holder connected to rest of syringe
- A61M2005/2488—Ampoule holder connected to rest of syringe via rotation, e.g. threads or bayonet
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/3129—Syringe barrels
- A61M2005/3142—Modular constructions, e.g. supplied in separate pieces to be assembled by end-user
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
- A61M5/31511—Piston or piston-rod constructions, e.g. connection of piston with piston-rod
- A61M2005/3152—Piston or piston-rod constructions, e.g. connection of piston with piston-rod including gearings to multiply or attenuate the piston displacing force
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/58—Means for facilitating use, e.g. by people with impaired vision
- A61M2205/581—Means for facilitating use, e.g. by people with impaired vision by audible feedback
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/58—Means for facilitating use, e.g. by people with impaired vision
- A61M2205/582—Means for facilitating use, e.g. by people with impaired vision by tactile feedback
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/24—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/3146—Priming, e.g. purging, reducing backlash or clearance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
- A61M5/31525—Dosing
- A61M5/31528—Dosing by means of rotational movements, e.g. screw-thread mechanisms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
- A61M5/31533—Dosing mechanisms, i.e. setting a dose
- A61M5/31535—Means improving security or handling thereof, e.g. blocking means, means preventing insufficient dosing, means allowing correction of overset dose
- A61M5/31543—Means improving security or handling thereof, e.g. blocking means, means preventing insufficient dosing, means allowing correction of overset dose piston rod reset means, i.e. means for causing or facilitating retraction of piston rod to its starting position during cartridge change
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
- A61M5/31565—Administration mechanisms, i.e. constructional features, modes of administering a dose
- A61M5/31566—Means improving security or handling thereof
- A61M5/31573—Accuracy improving means
Abstract
Disclosed is a resettable drug delivery device which is a pen-type injector. Resettable devices usually require a large number of component parts therefore making the devices large and bulky. The drug delivery device comprises a body (9, 11) having a resettable dose setting mechanism, cartridge holder (7) and means (13, 14) for releasably coupling the cartridge holder (7) to the body (9, 11) or the dose setting mechanism. The cartridge holder (7) receives a cartridge (8) containing at least one medicinal product. The means (13, 14) for releasably coupling the cartridge holder (7) to the body (9, 11) of the dose setting mechanism comprises a lug (13) formed on the cartridge holder (7) and the corresponding groove or slot (14) formed on the body (9, 11) or dose setting mechanism. The means (13, 14) are adapted and arranged such that an initial rotational coupling movement of the cartridge holder (7) relative to the body (9, 11) or the dose setting mechanism cause the cartridge holder (7) to move in a first axial direction relative to the body (9, 11) or the dose setting mechanism. A continued rotational coupling movement of the cartridge holder (7) relative to the body (9, 11) or the dose setting mechanism cause the cartridge holder (7) to move in a second axial direction which is contrary to the first axial direction relative to the body (9, 11) or the dose setting mechanism. er (7) and means (13, 14) for releasably coupling the cartridge holder (7) to the body (9, 11) or the dose setting mechanism. The cartridge holder (7) receives a cartridge (8) containing at least one medicinal product. The means (13, 14) for releasably coupling the cartridge holder (7) to the body (9, 11) of the dose setting mechanism comprises a lug (13) formed on the cartridge holder (7) and the corresponding groove or slot (14) formed on the body (9, 11) or dose setting mechanism. The means (13, 14) are adapted and arranged such that an initial rotational coupling movement of the cartridge holder (7) relative to the body (9, 11) or the dose setting mechanism cause the cartridge holder (7) to move in a first axial direction relative to the body (9, 11) or the dose setting mechanism. A continued rotational coupling movement of the cartridge holder (7) relative to the body (9, 11) or the dose setting mechanism cause the cartridge holder (7) to move in a second axial direction which is contrary to the first axial direction relative to the body (9, 11) or the dose setting mechanism.
Description
Drug Delivery Device
The present invention is directed to a drug delivery device, like a pen-type injector,
that provides for administration by injection of nal products from a ose
cartridge. The device comprises a dose setting mechanism which may have a hous-
ing, a dose setting member (number sleeve), a drive member (drive sleeve), a clutch
and a clicker.
There are lly two types of pen type delivery devices: resettable devices (i.e.,
reusable) and non-resettable (i.e., disposable). These types of pen delivery devices
(so named because they often resemble an enlarged fountain pen) are generally
sed of three primary elements: (i) a cartridge n that includes a cartridge
often contained within a housing or holder; (ii) a needle assembly connected to one
end of the cartridge section; and (iii) a dosing section with a dose g ism
ted to the other end of the dge section. A cartridge (often referred to as
an ampoule) typically includes a reservoir that is filled with a medication (e.g., insu—
lin), a movable rubber type bung or stopper located at one end of the cartridge res-
ervoir, and a top having a pierceable rubber seal located at the other, often necked-
down, end. A crimped annular metal band is typically used to hold the rubber seal in
place. While the cartridge housing may be typically made of plastic, cartridge reser-
voirs have historically been made of glass.
The closing n or dose setting mechanism is typically the portion of the pen
device that is used to set a dose. During an injection, a spindle contained within the
dose setting mechanism advances and presses against the bung or stopper of the
cartridge. This force causes the bung or stopper to advance, in turn causing the
medication contained within the cartridge to be injected through an attached needle
assembly.
Different types of pen delivery devices, including disposable (i.e., non—resettable)
and reusable (i.e., resettable) varieties, have evolved over the years. For example,
disposable pen delivery devices are supplied as self-contained devices. Such self-
contained devices do not have removable pre-filled cartridges. Rather, the pre-filled
cartridges may not be removed and replaced from these devices without destroying
the device itself. Consequently, such disposable devices need not have a resettable
dose setting mechanism.
In contrast to typical disposable pen type s, typical reusable pen delivery
devices feature essentially two main reusable components: a cartridge holder and a
dose setting mechanism. After a cartridge is inserted into the cartridge , this
cartridge holder is attached to the dose setting mechanism. The user uses the dose
setting mechanism to select a dose. Before the user injects the set dose, a e-
able -ended needle assembly is attached to the cartridge housing.
This needle assembly may be threaded onto or pushed onto (i.e., snapped onto) a
distal end of the cartridge housing. In this manner, a double ended needle mounted
on the needle assembly penetrated through a pierceable seal at a distal end of the
cartridge. After an injection, the needle ly is removed and discarded. After
the insulin in the cartridge has been exhausted, the user detaches the cartridge
housing from the dose setting mechanism. The user can then remove the empty
cartridge from the cartridge retainer and replace the empty cartridge with a new
(filled) dge.
Aside from replacing the empty cartridge with a new cartridge, the user must some-
how prepare the dose setting mechanism for a new cartridge: the dose setting
ism must be reset to a starting or l position. For example, in certain
typical resettable devices, in order to reset the dose setting mechanism, the e
(piston rod) that advances in a distal direction during dose injection must somehow
be retracted back proximally into the dose setting ism. n known meth-
ods of ting this spindle back into the dose setting ism to a restart or an
initial position are known in the art. As just one example, known reset mechanisms
require a user to turn back (i.e. screw or rotate) or push back (retract) the spindle or
some other portion of the dose setting mechanism.
Resetting of known dose setting mechanisms have certain perceived
disadvantages. One perceived disadvantage is that such able s use a
large number of component parts, such resettable devices tend to be large and
bulky, and therefore not easy to carry around or easy to conceal. Another
disadvantage may be seen in a priming step required prior to the first use of the
new cartridge.
Any sion of documents, devices, acts or knowledge in this specification is
included to n the context of the invention. It should not be taken as an
admission that any of the material formed part of the prior art base or the common
general knowledge in the relevant art in New Zealand on or before the priority date of
the claims herein.
Comprises/comprising and grammatical variations thereof when used in this
specification are to be taken to specify the presence of stated features, integers,
steps or components or groups thereof, but do not preclude the presence or addition
of one or more other features, integers, steps, components or groups thereof.
It would be desirable to provide an improved resetting mechanism for a reusable
drug delivery device.
The present invention is based upon a resetting mechanism that uses the initial
proximal movement of the piston rod (spindle) at the start of the resetting
procedure to decouple the dose g ism, e.g. the driver, in order to
permit the remainder of the resetting procedure to be completed. At the end of this
resetting procedure, the dose setting mechanism, e.g. its driver, must be fully recoupled
in order to ensure that the device works tely if the user dials and
dispenses the first dose from the new cartridge without priming. To re-couple the
dose setting mechanism, e.g. the driver, at the end of the resetting ure the
piston rod must be allowed to advance ly by a short distance out of the
mechanism, i.e. the reverse of the proximal movement at the start of the resetting
ure. e the device can be reset using the cartridge bung pressing on
the piston rod during attachment of the cartridge holder to the dose setting
mechanism there is potentially no space between the cartridge bung and the piston
rod that would allow the distal movement of the piston rod to age the dose
setting mechanism. Therefore, at the end of the ing procedure the cartridge bung
and hence cartridge holder must be 'backed-off’ slightly to allow the piston rod to
advance distally as mentioned above.
In accordance with the present invention, there is provided drug delivery device, having a
body, the body comprising a resettable dose setting mechanism, a cartridge holder for
ing a cartridge containing at least one medicinal product, and means for releasably
ng the dge holder to the body or the dose setting mechanism, wherein said
means are adapted and arranged such that an initial rotational coupling movement in a
rotating direction of the cartridge holder relative to the body or the dose setting
ism causes the cartridge holder to move in a first axial direction relative to the
body or the dose setting mechanism and wherein a continued rotational coupling
movement in the rotating direction of the cartridge holder relative to the body or the dose
setting mechanism causes the cartridge holder to move in a second axial direction, which
is in an opposite direction compared to the first axial direction, relative to the body or the
dose setting mechanism.
The first axial direction is typically contrary to the distal direction the piston or bung
moves within the cartridge during dispensing, i.e. the first axial ion is lly the
proximal direction.
According to a first embodiment, the means for releasably ng the cartridge
holder to the body and/or the dose setting mechanism comprise at least one lug and a
corresponding groove for receiving and guiding the lug and for effecting the movement
of the cartridge holder in the first and second axial directions upon relative rotation
between the cartridge holder and the body and/or the dose setting mechanism. In
other words, the groove defines a track or path in which the lug slides thus translating
a rotation into rotatory and translatory components. For this first embodiment, there
are different options how the lug and the groove may be provided to guide the
dge holder. It may be sufficient to guide the lug in the groove such that only one
face of the lug contacts one of the side walls of the tive groove. As an
alternative, te faces of the lug may be guided within the groove, i.e. like a
sliding block.
The present invention is not limited to the above-mentioned embodiment. Different
ways are possible to allow the piston rod during re-coupling of the mechanism to
advance distally by a short distance out of the mechanism, i.e. the e of the
proximal movement at the start of the resetting procedure. As an alternative to the
above-mentioned ment using lugs and grooves, the means for releasably
coupling the cartridge holder to the body may comprise corresponding pairs of
ramps or helical features provided on respective front faces of the body and
dge holder to move the cartridge holder in the second axial direction relative
to the body or the dose setting mechanism. Preferably, at least four pairs of
corresponding ramps or helical features are provided on respective front faces of
the body and cartridge holder. An advantage of not having lugs in grooves is that
when tolerances are allowed for the lugs will also be slightly loose. Having
separate l ramps placed further from the lugs to some extent allows the
plastic to flex slightly to accommodate slight erence enabling to design the
nominal condition to have a tight fit. Also these helical ramps on the cartridge
holder may be formed on a separate part of the mould tooling (ejector sleeve) and
the position or length of this sleeve can be adjusted in the tool so that the distance
from these helical ramps to the lugs on the cartridge holder matches the equivalent
distance between the aperture and helical ramps on the inner body.
As a further alternative, a slot may be provided, e.g. in the body, guiding a tongue
of the cartridge . The latter embodiment has the benefit of the tongue being
visible from outside of the body thus allowing a user to see r or not the
dge holder is correctly attached to the body.
Further, the means for releasably coupling the cartridge holder to the body and/or
the dose setting ism may comprise corresponding bayonet features formed
on the cartridge holder and the body or the dose setting mechanism, respectively.
Preferably, the means for releasably coupling the dge holder to the body
and/or the dose setting ism comprise a bayonet lug formed on the
cartridge holder and a groove formed on or in the body or the dose setting
mechanism.
According to one embodiment of the present invention, the means for releasably
coupling the cartridge holder to the body and/or the dose setting mechanism
comprise a groove having a first helical section with a first pitch and a second
helical section with a second pitch, with the first pitch being contrary to the second
pitch. In other words, if a lug or the like is moved within the groove, the lug moves
upon rotation in a first axial ion when being guided in the first n and
moves in the opposite (second) axial direction when being guided in the second
section.
Preferably, the first l section and the second helical section have a different
lead, i.e. the component of the axial movement of the combined rotator and transla-
tor movement is larger in one of the section, preferably in the first section.
In addition, a third section of the groove may be provided between the first helical
section and the second helical section with the third section having a lead differing
from the leads of the first helical section and the second l n.
According to a further embodiment, the drug delivery device further comprises
means for releasably rotationally fixing the cartridge holder to the body and/or the
dose setting mechanism. This prevents an unintended de-coupling of the dge
holder from the body and/or the dose setting mechanism. Typically, said means
comprise catching or snap-in means. Thus, the user may have to overcome a resis-
tance for fully coupling the cartridge holder to the body and/or the dose setting
mechanism. This provides for an audible and/or tactile feedback indicating that the
cartridge holder is attached to the body and/or the dose setting mechanism.
Preferably, the means for releasably rotationally fixing the cartridge holder to the
body and/or the dose setting mechanism comprise corresponding detent features
provided on the cartridge holder and the body and/or the dose setting mechanism,
respectively.
A compact and yet easy to handle drug delivery device may be provided, if the dose
setting mechanism comprises a piston rod and a driver, wherein the driver has two
driver components which are rotationally coupled to each other during dose setting
and dose dispensing and which are rotationally pled from each other during
ing of the dose g ism.
According to a preferred embodiment of this idea, a clutch may be provided for
onally coupling and de-coupling the two driver components, wherein de-
coupling of the two driver components requires a relative axial nt between
the two driver components. r, a spring means may be provided biasing the
two driver components to , wherein the spring force may be overcome when a
proximal force is applied to the piston rod, causing the driver components to le.
Thus, the spring means will tend to cause the driver components to auto—
matically re-couple when the al force is removed from the piston rod.
According to another embodiment, a spring means may be provided biasing the two
driver components to de-couple, wherein the cartridge holder causes the two driver
ents to couple if the cartridge holder is coupled or fully attached to the body
and/or the dose setting mechanism. Thus, the driver components automatically
couple when the cartridge holder is attached to the body and/or the dose setting
mechanism.
Preferably the movement of the cartridge holder in the second axial direction is
significant, i.e. greater than e.g. 0,2 mm, so as to ensure that the drive mechanism
can re-couple after reset.
In the following, the invention will be described by a way of an example and with
reference to the schematic drawings in which:
Figure 1 shows a side view of the driver of a drug ry device,
Figure 2 shows a side view of the cartridge holder during resetting and prior to
its attachment to a g component,
Figure 3 shows the cartridge holder beginning to engage with the housing com-
ponent
Figure 4 shows the device fully reset axially prior to the cartridge holder back off,
Figure 5 shows the device reset and the cartridge holder backed off,
Figure 6 shows a view from inside during assembly of the cartridge holder to
the housing component,
Figure 7 shows a view from inside with the components in their final locked
position after back off.
The drug delivery device 1 according to the present invention comprises a drive
sleeve having two components, a rear (proximal) half 2 and a front (distal) half 3.
Further, a coupling mechanism is provided for coupling and de-coupling the two
halves of the drive sleeve in on. This coupling mechanism is effectively a
clutch which may be engaged under the action of a spring 4, but which can be
disengaged if the front half 3 of the drive sleeve is moved towards the rear half 2,
compressing the spring 4 and de-coupling teeth 5 on the rear half 2 of the drive
sleeve from corresponding tooth features on a coupling component 6. Coupling
component 6 is fixed axially and rotationally, by means of snap features and
g splines respectively, to the front half 3 of the drive sleeve, causing the two
components 3, 6 to effectively behave as a single ent, hereafter 3. In the
example shown in Figure 1, the spring 4 is designed as a wave spring.
Figure 1 shows the drive sleeve halves 2, 3 in a coupled state, with the spring 4
essentially uncompressed (save for a small amount of compression applying a
biasing force to the drive sleeve coupling clutch) and the teeth 5 on the rear half 2
of the drive sleeve engaged with the teeth on the inside of the coupling component
Figure 2 shows the cartridge holder 7 with a fresh dge 8 during ing and
prior to its attachment to a housing component, e.g. an inner body of the device.
Further, a piston rod 10 is shown with one end protruding from the g
component. An outer body 11 which is a further housing component is shown
surrounding an end of the inner body 9. The inner body 9 and/or the outer body 11
may encase a dose g mechanism of the drug delivery device 1, i.e. the two
components 2, 3 of the drive sleeve, the piston rod 10 and further components, like
e.g. a dose dial sleeve and/or a clutch.
During device reset, when the cartridge is changed, the clutch is de-coupled by
pressing proximally on the piston rod 10 shown in Figure 2 by using for example a
finger or preferably the bung of the new cartridge 8 as it is ed to the
mechanism. The piston rod 10 engages with the front end 3 of the drive sleeve via
a helical thread form, and the rear end 2 of the drive sleeve is fixed rotationally and
axially ve to the mechanism during reset. Therefore as the piston rod 10 is
d into the device the front end of the drive sleeve 3 is axially translated in
the proximal direction and the clutch teeth 5 of the drive sleeve rear 2 initially
preventing rotation of the drive sleeve front 3 and ng component 6. Once the
proximal movement of the drive sleeve front 3 and coupling component 6 is
sufficient to decouple the clutch teeth 5 then the front half 3 of the drive sleeve and
the coupling component 6, driven by the helical thread on the piston rod 10, are
caused to rotate relative to the rear half 2 of the drive sleeve and spring 4 so as to
allow the piston rod 10 to be pressed back into the device further. Figure 2 shows
an embodiment of the mechanism where the piston rod 10 rotates during both
resetting and dose ry and therefore has a bearing 12 attached on its end
face to abut the cartridge bung (not shown).
When the cartridge 8 and hence piston rod 10 has been inserted into the
mechanism as far as it can go, the cartridge holder 7 must be locked off to hold the
cartridge 8 in position. This is achieved using a bayonet type connection, whereby
after essentially axial motion of the cartridge holder 7 relative to the mechanism,
the cartridge holder 7 is rotated to lock it into on against the g
component. However it is a requirement of the device that at the end of resetting,
the two halves 2, 3 of the drive sleeve are re-engaged, as shown in Figure 1,
during attachment of the cartridge holder 7. This is to ensure that if the user then
takes the device 1 and dials and ses a dose t first priming the
cartridge 8, then the dose they receive will be inside the ISO 11608-1 limits for
dose accuracy. If the two halves of the drive sleeve 2, 3 are not re-engaged after
the resetting procedure then the proximal distance moved by the drive sleeve front
3 in order to decouple clutch teeth 5 will be reversed during the delivery of the first
dose following resetting, causing a corresponding advance of the piston rod which
will deliver a small amount of drug in addition to the dose set by the user.
During reset, and if the user uses the cartridge bung to apply force to the piston
rod, when the piston rod 10 reaches its maximum proximal position the cartridge
bung and the bearing 12 on the end of the piston rod 10 will be in contact. In this
case the piston rod 10, and therefore the drive sleeve front 3 which is threaded to
the piston rod 10, cannot advance in the distal direction and therefore the drive
sleeve halves 3, 6 cannot re-engage. In this case the re-engagement of the drive
sleeve halves 2, 3 at the end of reset can only be achieved by moving the dge
holder 7 and hence cartridge 8 back away from of the mechanism by an amount
that enables the drive sleeve front 3, biased by action of the spring 4, to move
axially away from drive sleeve rear 2 to allow the clutch teeth 5 to re-engage. This
reverse motion of the cartridge holder 7 is referred to from now on as 'back off' and
is essentially an axial movement in the opposite direction to attachment of the
cartridge holder 7 during resetting of the device (i.e. the distal direction).
This 'back off' is achieved by providing bayonet features comprising bayonet lugs 13
formed on the cartridge holder 7 and corresponding bayonet grooves 14 ) which
are formed on or in the inner body 9. The bayonet lugs 13 and the t grooves
14 constitute means for releasably coupling the cartridge holder to the body 9, 11 or
the dose setting mechanism. Groove 14 has a first helical section 14a having a first
pitch (to the upper right in Figure 2) and a second helical section 14b having a
, opposite pitch (to the lower right in Figure 2). In addition to the first pitch
being contrary to the second pitch, the first helical section 14a and the second helical
section 14b have a different lead as the first helical n 14a is steeper compared
to the second helical section 14b. ally, a third section 14c of the groove 14 is
provided interposed n the first helical section 14a and the second helical
n 14b. This third section 14c has substantially no lead or a small lead. Hence,
as a lug 13 travels within a groove 14, the cartridge holder 7 and the body 9, 11 move
towards each other when the lug 13 is guided within the first helical section 14a, the
cartridge holder 7 and the body 9, 11 rotate with substantially no
relative axial movement when the lug 13 is guided within the third section 14c, and
the dge holder 7 and the body 9, 11 move away from each other when the lug
13 is guided within the second helical section 14b.
In addition or as an alternative to the design of the grooves 14 having at least a first
and a second section with a different pitch, the 'back off' is achieved by the helical
ramp-like features 17, 18 depicted in Figure 7. Hence, it is not necessary that the
lugs 13 are in contact with the ed walls of the respective second helical sec-
tions 14b to guide the lugs. Thus, as an alternative to the second helical sections
14b, a clearance may be provided allowing the lugs 13 to travel in the distal ion
during the 'back off' step at the end of the rotation.
The lugs 13 may have a oidal form adapted to the lead of the first and/or
second helical sections as shown in Figures 2 to 7 to improve guidance in the
groove 14. Further, one side face of the lug 13 may be adapted to the end wall of
the second helical section 14b thus forming an abutment or stop face at the end of
groove 14.
Figure 3 to Figure 5 illustrate the sequence of events during the attachment of the
cartridge holder 7 to the inner body 9. Figure 3 shows a position of the cartridge
holder 7 and the inner body 9 where the lugs 13 on cartridge holder 7 begin to en-
gage with inner body bayonet features 14. In Figure 4 the device is fully reset axially
prior to 'back off' (at this point the drive sleeve clutch teeth 5 would be disengaged).
Figure 5 shows the device reset and 'backed off' with the bayonet features fully
attached (at this point the drive sleeve clutch teeth 5 would be re-engaged as shown
in Figure 1). Figures 4 and 5 show how the lug 13 on the cartridge holder 7 slides
down a slope within groove 14 that allows it to 'back off' by 0,5 mm. This 'back off'
enables the reset clutch to re-engage as shown in Figure 1. This is possible be-
cause as the cartridge holder 7 is 'backed off' by 0,5 mm, thus allowing the piston
rod 10 and its bearing 12 to advance 0,5 mm.
In this , due to the interaction between the piston rod 10, the inner body 9 and
the front half 3 of the drive sleeve, there is a gearing ratio between the axial move-
ment of the piston rod and the axial movement of the front half of the drive sleeve 3.
In this embodiment the 0,5 mm distal movement of the piston rod 10 causes a
greater distal movement of 1,0 mm of the front half 3 of the drive sleeve away from
the rear half 2 of the drive sleeve which is sufficient to fully re-engage the reset
clutch under the biasing force of the spring 4.
Figures 6 and 7 illustrate the same sequence of reset operation viewed from inside
the device with the parts sectioned. These figures highlight helical features 17 on the
inner body (and corresponding features 18 on the end face of the cartridge holder 7)
that help to guide the cartridge holder 7 during 'back off' and support the cartridge
holder 7 when fully attached by reacting axial force from end face of dge holder
7. l features 17, 18 may be designed as corresponding ramps provided be—
tween inner body 9 and cartridge holder 7 to ensure that the t lug 13 follows
the "back off" slope with minimal axial play. ably, four or more pairs of corre-
sponding ramps 17, 18 are provided. Further, (detent) es 15, 16, on the inner
body 9 and cartridge holder 7 respectively, for releasably onally fixing the car-
tridge holder 7 to the body 9, 11 or the dose setting mechanism are depicted.
In Figure 6 the device is shown during reset with the cartridge holder 7 initially as-
d axially into the inner body 9 and when the bayonet lugs 13 on the cartridge
holder 7 engage with slots 14 in the inner body. Thus, the cartridge holder 7 is
guided to take a helical path upon relative rotation of the cartridge holder 7 and the
inner body 9.
Detent features 15, 16 are provided on the cartridge holder 7 and the inner body 9,
respectively. The detent features 15, 16 may "snap in" or align when the cartridge
holder 7 is fully rotated in its final locking position in the inner body 9. This prevents
an unintended de-coupling of the cartridge holder 7 from the body 9, 11 and/or the
dose setting mechanism. The detent features 15, 16 depicted in Figures 6 and 7
work like catching or snap—in means. Thus, the user has to overcome a resistance
for fully coupling the cartridge holder 7 to the body 9, 11 and/or the dose setting
mechanism. This provides for an audible and/or tactile feedback indicating that the
cartridge holder 7 is correctly attached to the body 9, 11 and/or the dose setting
mechanism.
As shown in Figure 6, the detent features 15, 16 are clear of each other but are just
about to start engagement when the lug 13 is within the first helical section 14a or
the third section 140 of the groove 14. In Figure 7 the bayonet features 13, 14 are in
their final position and the detent features 15, 16 are in their final detent position,
too. Thus, all parts are in their final locked position after 'back off'. The device 1 is
reset and ready to be used even without priming. However, a priming step may still
be ed or advisable for other reasons such as checking that the needle is not
blocked and that the pen mechanism is working etc. Thus, the user should now
prime the device to ensure that it is operating correctly and . However, in the
event that the user does not prime the device before use (either user forgets to
prime or deliberately omits the priming step) the ‘back-off’ of the cartridge holder
should still ensure that the first dose received is within the ISO—11608 specified
limits for dose accuracy.
The terms ,,medicament“ or cinal product“, as used herein, mean a pharmaceu—
tical formulation containing at least one pharmaceutically active compound,
wherein in one embodiment the pharmaceutically active compound has a molecular
weight up to 1500 Da and/or is a peptide, a ne, a polysaccharide, a vaccine, a
DNA, a RNA, an enzyme, an antibody or a fragment thereof, a e or an
oligonucleotide, or a e of the above-mentioned pharmaceutically active com-
pound,
wherein in a further embodiment the ceutically active compound is useful for
the treatment and/or prophylaxis of diabetes mellitus or cations associated
with diabetes mellitus such as diabetic retinopathy, thromboembolism disorders such
as deep vein or pulmonary thromboembolism, acute coronary syndrome (ACS),
angina, myocardial infarction, , macular degeneration, inflammation, hay
fever, atherosclerosis and/or toid arthritis,
wherein in a further embodiment the pharmaceutically active compound comprises
at least one peptide for the treatment and/or prophylaxis of diabetes mellitus or
complications associated with diabetes mellitus such as diabetic retinopathy,
wherein in a further embodiment the pharmaceutically active compound comprises
at least one human insulin or a human insulin analogue or derivative, glucagon-like
peptide (GLP-1) or an analogue or tive thereof, or exendin-3 or exendin-4 or
an analogue or derivative of n-3 or exendin-4.
Insulin ues are for example Gly(A21), Arg(831), Arg(832) human insulin;
Lys(BB), Glu(829) human insulin; Lys(BZ8), Pro(829) human insulin; Asp(BZ8)
human insulin; human insulin, wherein e in position B28 is replaced by Asp,
Lys, Leu, Val or Ala and wherein in position 829 Lys may be replaced by Pro;
Ala(826) human insulin; Des(BZ8—BBO) human n; Des(B27) human insulin and
Des(BBO) human n.
Insulin tes are for example BZQ-N-myristoyl—des(BBO) human insulin; BZQ-N-
palmitoyl-des(BBO) human insulin; BZQ-N-myristoyl human insulin; BZQ-N-palmitoyl
human insulin; myristoyl Pr0829 human insulin; BZ8—N-palmitoyl-
LysBZBProBZQ human insulin; BBO-N-myristoyl-ThrBZQLysBBO human insulin; 330—
N-palmitoyl- ThrBZQLysBSO human insulin; BZQ-N-(N-palmitoyl-Y—glutamyl)-
des(BBO) human insulin; BZQ—N-(N—lithocholyl—Y-glutamyl)-des(BBO) human insulin;
BZQ-N-(w—carboxyheptadecanoyl)-des(BSO) human insulin and BZQ-N-(w-
carboxyheptadecanoyl) human insulin.
Exendin-4 for example means Exendin—4(1-39), a peptide of the sequence H-His-
Gly-Glu-Gly-Thr—Phe-Thr—Ser-Asp-Leu-Ser-Lys—Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-
Leu—Phe-lle—Glu-Trp—Leu-Lys-Asn-Gly-Gly—Pro—Ser-Ser-Gly—Ala-Pro-Pro—Pro-Ser-
NH2.
Exendin-4 derivatives are for example selected from the following list of compounds:
H-(Lys)4-des Pr036, des Pr037 Exendin-4(1-39)-NH2,
H—(Lys)5—des Pr036, des Pr037 n-4(1-39)-NH2,
des Pr036 Exendin-4(1-39),
des Pr036 [Asp28] Exendin-4(1-39),
des Pr036 [|soAsp28] Exendin—4(1—39),
des Pr036 [Met(O)14, Asp28] Exendin-4(1-39),
des Pro36 [Met(O)14, |soAsp28] Exendin-4(1-39),
des Pro36 [Trp 02)25, Asp28] Exendin-4(1—39),(
des Pr036 [Trp 02)25, |soAsp28] Exendin-4(1—39),(
des Pr036 [Met(O)14 Trp(02)25, Asp28] n-4(1-39),
des Pro36 [Met O)14 )25, |soAsp28] Exendin-4(1—39); or(
des Pr036 [Asp28] Exendin-4(1-39),
des Pr036 [|soAsp28] Exendin-4(1-39),
des Pr036 [Met(O)14, Asp28] Exendin-4(1-39),
des Pr036 [Met(O)14, |soAsp28] Exendin-4(1—39),
des Pr036 [Trp(02)25, Asp28] n-4(1-39),
des Pr036 [Trp(02)25, |soAsp28] Exendin-4(1-39),
des Pr036 [Met(O)14 Trp(02)25, Asp28] Exendin-4(1-39),
des Pr036 [Met(O)14 Trp(02)25, 28] Exendin-4(1-39),
wherein the group -Lys6—NH2 may be bound to the inus of the Exendin-4
derivative;
or an Exendin-4 derivative of the sequence
des Pr036 Exendin-4(1-39)-Lys6-NH2 (AVEOO10),
H-(Lys)6-des Pr036 [Asp28] Exendin-4(1-39)-Lys6—NH2,
des Asp28 Pr036, Pr037, Pro38Exendin-4(1-39)-NH2,
H-(Lys)6-des Pr036, Pr038 [Asp28] Exendin—4(1—39)-NH2,
H-Asn-(Glu)5des Pr036, Pr037, Pr038 ] Exendin—4(1-39)-NH2,
des Pr036, Pr037, Pr038 [Asp28] Exendin-4(1-39)-(Lys)6—NH2,
H-(Lys)6—des Pr036, Pr037, Pr038 [Asp28] Exendin-4(1-39)—(Lys)6-NH2,
(GIu)5—des Pr036, Pr037, Pr038 [Asp28] n-4(1-39)—(Lys)6—NH2,
H-(Lys)6-des Pr036 [Trp(02)25, Asp28] Exendin-4(1-39)-Lys6-NH2,
H—des Asp28 Pr036, Pr037, Pr038 [Trp(02)25] n-4(1—39)—NH2,
H-(Lys)6—des Pr036, Pr037, Pr038 [Trp(02)25, Asp28] Exendin-4(1-39)-NH2,
H-Asn-(GIu)5-des Pr036, Pr037, Pr038 [Trp(02)25, Asp28] Exendin-4(1-39)-NH2,
des Pr036, Pr037, Pr038 2)25, Asp28] Exendin-4(1—39)—(Lys)6—NH2,
H-(Lys)6-des Pr036, Pr037, Pr038 2)25, Asp28] Exendin-4(1-39)-(Lys)6—NH2,
H-Asn-(GIu)5-des Pr036, Pr037, Pr038 [Trp(02)25, Asp28] Exendin-4(1-39)-(Lys)6-
NH2,
H-(Lys)6-des Pr036 [Met(O)14, Asp28] Exendin-4(1—39)-Lys6—NH2,
des Met(O)14 Asp28 Pr036, Pr037, Pr038 Exendin-4(1-39)-NH2,
H—(Lys)6-desPr036, Pr037, Pr038 [Met(O)14, Asp28] Exendin—4(1—39)—NH2,
H-Asn-(GIu)5—des Pr036, Pr037, Pr038 [Met(O)14, Asp28] Exendin-4(1-39)-NH2,
des Pr036, Pr037, Pr038 [Met(O)14, Asp28] Exendin-4(1-39)-(Lys)6-NH2,
H-(Lys)6-des Pr036, Pr037, Pr038 [Met(O)14, Asp28] Exendin—4(1—39)-(Lys)6-NH2,
H-Asn-(Glu)5 des Pr036, Pr037, Pr038 [Met(O)14, Asp28] Exendin-4(1-39)-(Lys)6-
NH2,
H-Lys6-des Pr036 [Met(O)14, Trp(02)25, Asp28] Exendin-4(1-39)—Lys6—NH2,
H-des Asp28 Pr036, Pr037, Pr038 )14, )25] Exendin-4(1-39)—NH2,
H—(Lys)6—des Pr036, Pr037, Pr038 [Met(O)14, Asp28] Exendin-4(1-39)-NH2,
H-Asn—(GIu)5—des Pr036, Pr037, Pr038 [Met(O)14, Trp(02)25, Asp28] Exendin-4(1-
39)—NH2,
des Pr036, Pr037, Pr038 [Met(O)14, Trp(02)25, Asp28] Exendin-4(1-39)—(Lys)6—
NH2,
H-(Lys)6—des Pr036, Pr037, Pr038 [Met(O)14, Trp(02)25, Asp28] Exendin-4(S1-39)-
(Lys)6-NH2,
H-Asn-(GIu)5—des Pr036, Pr037, Pr038 [Met(O)14, Trp(02)25, Asp28] Exendin-4(1-
39)—(Lys)6-NH2;
or a pharmaceutically acceptable salt or solvate of any one of the afore-mentioned
Exendin-4 derivative.
Hormones are for example hypophysis hormones or hypothalamus hormones or
regulatory active peptides and their antagonists as listed in Rote Liste, ed. 2008,
Chapter 50, such as Gonadotropine (Follitropin, Lutropin, Choriongonadotropin,
Menotropin), opine (Somatropin), Desmopressin, Terlipressin, Gonadorelin,
Triptorelin, Leuprorelin, Buserelin, Nafarelin, Goserelin.
A polysaccharide is for example a glucosaminoglycane, a hyaluronic acid, a heparin,
a low molecular weight heparin or an ultra low molecular weight heparin or a deriva—
tive thereof, or a sulphated, e.g. a poly-sulphated form of the above-mentioned
polysaccharides, and/or a pharmaceutically acceptable salt thereof. An example of a
pharmaceutically acceptable salt of a poly—sulphated low lar weight heparin is
enoxaparin sodium.
Antibodies are globular plasma proteins (~150 kDa) that are also known as immu-
ulins which share a basic structure. As they have sugar chains added to
amino acid residues, they are roteins. The basic functional unit of each anti—
body is an immunoglobulin (lg) r (containing only one lg unit); secreted
antibodies can also be dimeric with two lg units as with lgA, tetrameric with four lg
units like teleost fish lgM, or pentameric with five lg units, like ian lgM.
The lg monomer is a "Y"-shaped molecule that consists of four polypeptide chains;
two identical heavy chains and two identical light chains connected by ide
bonds between cysteine es. Each heavy chain is about 440 amino acids long;
each light chain is about 220 amino acids long. Heavy and light chains each contain
intrachain disulfide bonds which stabilize their folding. Each chain is composed of
structural domains called lg domains. These domains contain about 70-110 amino
acids and are classified into different ries (for example, variable or V, and
constant or C) according to their size and function. They have a characteristic im—
munoglobulin fold in which two B sheets create a “sandwich” shape, held together by
interactions between conserved cysteines and other charged amino acids.
There are five types of mammalian Ig heavy chain d by d, 6, a, v, and p. The
type of heavy chain present defines the isotype of antibody; these chains are found
in lgA, lgD, lgE, lgG, and lgM antibodies, respectively.
ct heavy chains differ in size and composition; or and v n approximately
450 amino acids and 6 approximately 500 amino acids, while u and a have approxi—
mately 550 amino acids. Each heavy chain has two regions, the constant region
(CH) and the variable region (VH). In one s, the constant region is essentially
identical in all antibodies of the same isotype, but differs in antibodies of different
isotypes. Heavy chains v, d and 6 have a constant region composed of three tandem
lg domains, and a hinge region for added flexibility; heavy chains p and a have a
constant region composed of four immunoglobulin domains. The variable region of
the heavy chain differs in antibodies produced by different B cells, but is the same
for all antibodies produced by a single B cell or B cell clone. The variable region of
each heavy chain is approximately 110 amino acids long and is composed of a
single lg domain.
In mammals, there are two types of globulin light chain denoted by A and K.
A light chain has two successive domains: one constant domain (CL) and one vari-
able domain (VL). The approximate length of a light chain is 211 to 217 amino acids.
Each antibody contains two light chains that are always identical; only one type of
light chain, K or A, is present per antibody in mammals.
Although the general structure of all antibodies is very r, the unique property of
a given antibody is determined by the variable (V) s, as detailed above. More
specifically, variable loops, three each the light (VL) and three on the heavy (VH)
chain, are responsible for binding to the n, i.e. for its antigen specificity. These
loops are referred to as the Complementarity ining Regions (CDRs). Be—
cause CDRs from both VH and VL domains contribute to the antigen-binding site, it
is the combination of the heavy and the light chains, and not either alone, that de-
termines the final antigen specificity.
An ody fragment” contains at least one antigen binding fragment as defined
above, and exhibits essentially the same function and specificity as the te
antibody of which the fragment is derived from. Limited proteolytic digestion with
papain cleaves the Ig prototype into three fragments. Two identical amino terminal
fragments, each containing one entire L chain and about half an H chain, are the
antigen binding fragments (Fab). The third fragment, similar in size but containing
the carboxyl terminal half of both heavy chains with their interchain disulfide bond, is
the crystalizable nt (F0). The Fc contains carbohydrates, ment-
binding, and FcR—binding sites. Limited pepsin digestion yields a single F(ab')2
fragment containing both Fab pieces and the hinge region, ing the H—H inter-
chain disulfide bond. 2 is divalent for antigen binding. The disulfide bond of
F(ab')2 may be cleaved in order to obtain Fab'. Moreover, the variable regions of the
heavy and light chains can be fused er to form a single chain variable frag-
ment (scFv).
Pharmaceutically acceptable salts are for example acid addition salts and basic
salts. Acid addition salts are e.g. HCl or HBr salts. Basic salts are e.g. salts having a
cation selected from alkali or alkaline, e.g. Na+, or K+, or Ca2+, or an ammonium
ion N+(R1)(R2)(R3)(R4), wherein R1 to R4 independently of each other mean: hy—
drogen, an optionally substituted Cl-CS-alkyl group, an optionally substituted C2—
C6-alkenyl group, an optionally substituted C6-C10-aryl group, or an optionally
substituted -heteroaryl group. Further examples of pharmaceutically accept-
able salts are described in gton's Pharmaceutical es" 17. ed. Alfonso
R. Gennaro (Ed), Mark Publishing Company, Easton, Pa., USA, 1985 and in
Encyclopedia of Pharmaceutical Technology.
Pharmaceutically acceptable solvates are for example hydrates.
Reference numerals:
drug ry device
rear end of the drive sleeve
front end of the drive sleeve
spnng
coupling teeth (clutch)
CDVCDO‘IAOONA coupling ent (clutch)
cartridge holder
canndge
inner body (housing component)
piston rod
44444“) LOON—‘ko outer body (housing component)
piston rod bearing
lug (bayonet feature)
groove/slot (bayonet feature)
14a first helical section
14b second helical section
14c third section
,16 detent features
17,18 helical support faces (ramps)
Claims (19)
1. Drug delivery device, having a body, the body comprising a resettable dose setting ism, a cartridge holder for receiving a cartridge ning at least one medicinal product, and means for releasably coupling the cartridge holder to the body or the dose setting mechanism, wherein said means are d and arranged such that an initial rotational coupling movement in a rotating direction of the cartridge holder relative to the body or the dose setting mechanism causes the cartridge holder to move in a first axial direction relative to the body or the dose setting mechanism and wherein a continued rotational coupling movement in the rotating direction of the cartridge holder relative to the body or the dose setting mechanism causes the cartridge holder to move in a second axial direction, which is in an opposite direction compared to the first axial direction, relative to the body or the dose setting mechanism.
2. Drug delivery device according to claim 1, wherein the means for ably coupling the cartridge holder to the body or the dose setting ism comprise at least one lug and a corresponding groove or slot for receiving and guiding the lug and for effecting movement of the cartridge holder in the first and second axial directions upon relative rotation between the cartridge holder and the body or the dose setting ism.
3. Drug delivery device according to claim 1, wherein the means for releasably coupling the cartridge holder to the body or the dose setting mechanism se corresponding bayonet features formed on the cartridge holder and the body or the dose setting mechanism, tively.
4. Drug delivery device according to claim 1, wherein the means for releasably coupling the cartridge holder to the body or the dose setting mechanism se a bayonet lug formed on the cartridge holder and a groove or slot formed on or in the body or the dose setting mechanism.
5. Drug delivery device according to claim 1, n the means for releasably coupling the dge holder to the body or the dose setting mechanism se a groove or slot having a first helical section having a first pitch and a second helical section having a second pitch, with the first pitch being contrary to the second pitch.
6. Drug delivery device according to claim 5, wherein the first helical section and the second helical section have a different lead.
7. Drug delivery device according to either claim 5 or 6, wherein a third section of the groove or slot is provided between the first helical section and the second 5 helical section with the third section having a lead differing from the leads of the first helical section and the second helical section.
8. Drug delivery device according to any one of the preceding claims further comprising means for ably rotationally fixing the cartridge holder to the body or the dose g mechanism. 10
9. Drug delivery device according to claim 8, wherein the means for releasably rotationally fixing the cartridge holder to the body or the dose setting mechanism comprise corresponding detent features provided on the cartridge holder and the body or the dose setting mechanism, respectively.
10. Drug delivery device according to any one of the preceding claims, wherein 15 the means for ably coupling the cartridge holder to the body comprise corresponding pairs of ramps or helical features ed on respective front faces of the body and cartridge holder to move the cartridge holder in the second axial direction relative to the body or the dose setting ism.
11. Drug delivery device according to claim 10, wherein at least four pairs of 20 corresponding ramps are provided on respective front faces of the body and dge holder.
12. Drug delivery device according to any one of the preceding claims, the dose setting mechanism comprising a piston rod and a driver, wherein the driver comprises two driver ents which are rotationally coupled to each other during 25 dose setting and dose dispensing and which are rotationally de-coupled from each other during ing of the dose setting mechanism.
13. Drug delivery device according to claim 12, wherein a clutch is provided for coupling and pling the two driver components, wherein de-coupling of the two driver components requires a relative axial movement between the two driver components. 5
14. Drug ry device according to either claim 12 or 13, wherein the relative axial movement between the two driver components to effect de-coupling is provided by the axial or helical movement of the piston rod.
15. Drug delivery device according to either claim 12 or 13, wherein a spring means is provided biasing the two driver components into the coupled position. 10
16. Drug delivery device according to either claim 12 or 13, n a spring means is provided biasing the two driver components to de-couple, wherein the dge holder causes the two driver components to couple if the cartridge holder is coupled to the body or the dose setting mechanism.
17. Drug ry device according to any one of claims 1-11, wherein the 15 movement of the cartridge holder in the second axial direction is significant so as to ensure that the drive mechanism can re-couple after reset.
18. Drug ry device according to any one of the ing claims wherein the cartridge containing a medicinal product is received in the cartridge holder.
19. A drug ry device, substantially as hereinbefore described with reference 20 to the accompanying drawings. SANOFI-AVENTIS DEUTSCHLAND GMBH WATERMARK PATENT AND TRADE MARKS ATTORNEYS P37968NZ00
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11159757 | 2011-03-25 | ||
EP11159757.1 | 2011-03-25 | ||
PCT/EP2012/055056 WO2012130704A1 (en) | 2011-03-25 | 2012-03-22 | Drug delivery device |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ616166A NZ616166A (en) | 2014-12-24 |
NZ616166B2 true NZ616166B2 (en) | 2015-03-25 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2012234468B2 (en) | Drug delivery device | |
CN105744975B (en) | Drug delivery device with dose knob clutch | |
CN106794309B (en) | Medicament injection device with a reset mechanism allowing retraction of the piston rod when changing a cartridge | |
JP6754357B2 (en) | How to assemble a drive sleeve, drug delivery device, and drug delivery device | |
JP2017520370A (en) | Spring arrangement and drug delivery device having spring arrangement | |
JP2017520374A (en) | Drug delivery device | |
JP2016529013A (en) | Housing and cap for injection devices made of outer metal member and inner plastic member | |
JP2018505026A (en) | Drive mechanism for injection device | |
JP2017534364A (en) | Housing, drug delivery device having housing, and method of manufacturing housing | |
JP6722180B2 (en) | Drug delivery device | |
CN111315431A (en) | Injection device | |
JP6717822B2 (en) | Display and drug delivery device having a display | |
CN106794308B (en) | Resettable drug delivery device | |
CN105682713B (en) | Assembly for a drug delivery device | |
JP2017530800A (en) | Insert and drug delivery device having an insert | |
CN112739398B (en) | injection device | |
TW201545783A (en) | Assembly for a drug delivery device and drug delivery device | |
JP2017530799A (en) | Drive mechanism and drug delivery device having drive mechanism | |
NZ616166B2 (en) | Drug delivery device | |
CN112512609B (en) | Drug delivery device and assembly method for a drug delivery device | |
CN111902171B (en) | Injection device | |
RU2794029C2 (en) | Drug delivery device and assembly method for drug delivery device | |
JP2021534894A (en) | Improved weighing mechanism and injection device |